Lenalidomide for treatment of myelodysplastic syndromes

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3198-3203

  Komrokji, Rami S ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Deletion 5q; Lenalidomide; Myelodysplastic syndromes; Non del(5q)

Indexed keywords

AZACITIDINE; DIGOXIN; ERYTHROPOIETIN; LENALIDOMIDE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN TYROSINE PHOSPHATASE; RIBOSOMAL PROTEIN S14; RIBOSOME PROTEIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHROMOSOME 5Q; CHROMOSOME LOSS; CYTOGENETICS; DRUG MECHANISM; DRY SKIN; ERYTHROCYTE TRANSFUSION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NEUTROPENIA; NONHUMAN; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SCALP PRURITUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84862570201     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023198     Document Type: Article

References (38)

1. Bennett JM, Komrokji RS. The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment. Hematology 2005; 10 Suppl 1: 258-69.
2. Bennett JM, List AF, for the Myelodysplastic Syndromes Foundation I. Disparities in C-criteria for initiating chelation therapy for iron overload in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts 2005; 106: 2535
3. John MB, for the MDSFsWGoTIO. Consensus statement on iron overload in myelodysplastic syndromes. American Journal of Hematology 2008; 83: 858-61.
4. Melchert M, List AF. Management of RBC-transfusion dependence. Hematology 2007; 2007: 398-404.
5. Bennett JM, Komrokji R, Kouides P. The myelodysplastic syndromes. In: Abeloff M. D. AJO, Niederhuber J. E., ed. Clincial oncology. Vol. Third. New york: Churchill Livingstone; 2004: 2849-81.
6. Melchert M, List A. The thalidomide saga. The international journal of biochemistry & cell biology 2007; 39: 1489-99.
7. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251: 437-8.
8. Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q-syndrome: delineation of the critical region on 5q and identification of a 5q-breakpoint. Genomics 1994; 19: 425-32.
9. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med; 363: 1025-37.
10. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008; 451: 335-9.
11. Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood; 117: 2567-76.
12. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med; 16: 59-66.
13. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med; 16: 49-58.
14. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. The New England journal of medicine 2005; 352: 549-57.
15. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer control: journal of the Moffitt Cancer Center 2006; 13 Suppl: 4-11.
16. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England journal of medicine 2006; 355: 1456-65.
17. Sekeres MA, Maciejewski JP, Giagounidis AAN, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26: 5943-9.
18. Giagounidis A, Fenaux P, Mufti GJ, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008; 87: 345-52.
19. Komrokji R, Giagounidis A, List A. Lenalidomide therapy in MDS. In: Steensma DP, ed. Myelodysplastic syndromes: pathobiology and clinical management (ed 2nd). London: Informa Health Care; 2008: 457-83.
20. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Journal of clinical pharmacology 2007; 47: 1466-75.
21. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118(14): 3765-76. Epub 2011 Jul 13
22. Burcheri S, Prebet T, Beyne-Rauzy O, et al. Lenalidomide (LEN) in int 2 and high risk MDS with del 5q. Interim results of a phase II trial by the GFM. ASH Annual Meeting Abstracts 2007; 110: 820.
23. Mollgard L, Saft L, Treppendahl MB, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica; 96: 963-71.
24. Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood; 118: 523-8.
25. Gohring G, Giagounidis A, Aul C, et al. Long-term cytogenetic follow-up of MDS patients with 5qtreated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to complex clones and progression to AML. ASH Annual Meeting Abstracts 2008; 112: 1647
26. List A WK, Dewald G, Bennett J, Giagounidis A, Kurtin S, Knight R. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leukemia Research 2007; 31: s38.
27. Ades L, Lebras F, Sebert M, et al. Risk of AML evolution in lower risk MDS with del 5q treated with or without lenalidomide. A report by the Groupe Francophone Des Myelodysplasies (GFM). ASH Annual Meeting Abstracts; 116: 976
28. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol; 29: 1971-9.
29. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009.
30. Ferreira-Cerca S, Hurt E. Cell biology: Arrest by ribosome. Nature 2009; 459: 46-7.
31. List AF, Rocha K, Zhang L, et al. Secondary resistance to lenalidomide in del(5q) MDS is associated with CDC25C & PP2A overexpression. ASH Annual Meeting Abstracts 2009; 114: 292
32. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Journal of Clinical Oncology; 28: 2253-8.
33. Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of highdose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood; 117: 1828-1833.
34. Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009; 113: 1002-5.
35. Hoefsloot LH, van Amelsvoort MP, Broeders LC, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997; 89: 1690-700.
36. Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. The Journal of clinical investigation 2008; 118: 248-58.
37. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: e35.
38. List AF, Lancet JE, Melchert M, et al. Two-stage pharmacokinetic & efficacy study of lenalidomide alone or combined with recombinant erythropoietin (EPO) in lower risk MDS EPO-failures [PK002]. ASH Annual Meeting Abstracts 2007; 110: 4626.